CNS & Neurological Disorders - Drug Targets

Author(s): Nick Pantaleo, Wayne Chadwick, Sung-Soo Park, Liyun Wang, Yu Zhou, Bronwen Martin and Stuart Maudsley

DOI: 10.2174/187152710793361504

The Mammalian Tachykinin Ligand-Receptor System: An Emerging Target for Central Neurological Disorders

Page: [627 - 635] Pages: 9

  • * (Excluding Mailing and Handling)

Abstract

Our understanding of the complex signaling neurophysiology of the central nervous system has facilitated the exploration of potential novel receptor-ligand system targets for disorders of this most complex organ. In recent years, many relatively neglected receptor-ligand systems have been re-evaluated with respect to their ability to potently modulate discrete tracts in the central nervous system. One such system is the tachykinin (previously neurokinin) system. The multiple heptahelical G protein-coupled receptors and neuropeptide ligands that comprise this system may be significantly involved in more central nervous systems actions than previously thought, including sleep disorders, amyotrophic lateral sclerosis, Alzheimers disease and Machado-Joseph disease. The development of our understanding of the role of the tachykinin receptor-ligand system in higher order central functions is likely to allow the creation of more specific and selective tachykinin-related neurotherapeutics.

Keywords: Central neurological disorders, substance P, neurokinin A, neurokinin B, neurotherapeutics, receptor-ligand systems, tachykinin